The study published in the Journal of Pain Research was led by Geoffroy Laumet of Michigan State University. Using a mouse model, the researchers compared recovery after a small surgical incision with normal TNF-α activity and with the molecule blocked.
They inhibited TNF-α by three different methods, including Etanercept, an FDA-approved drug used in humans. The team expected less pain when TNF-α was blocked. Instead, mice with TNF-α blocked experienced much longer pain. Laumet explains that blocking the molecule prevented the body from turning off pain in the normal way. The result appeared in repeated experiments by several lab members and with different inhibition methods.
The authors note that pain after surgery resolves for most people, but some develop chronic postsurgical pain. They warn the findings do not mean stopping all anti-inflammatory treatment and call for therapies that block harmful molecules while preserving helpful ones.
Difficult words
- molecule — a very small particle in a living body
- inhibit — to stop or slow a process or actioninhibited
- chronic — continuing for a long time, not short
- postsurgical — happening after a surgical operation
- resolve — to end or get better over timeresolves
- anti-inflammatory — reducing swelling and inflammation in the body
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- How could doctors balance blocking harmful molecules while preserving helpful ones after surgery?
- Would you prefer a treatment that reduces immediate pain even if it might cause longer pain? Why or why not?
- What questions would you ask your doctor about anti-inflammatory drugs before surgery?
Related articles
Forest loss in tropics raises local heat and deaths
A study using satellite data found that tropical deforestation from 2001–2020 exposed 345 million people to local warming and likely caused about 28,000 heat-related deaths per year, mainly in Africa, Southeast Asia and Latin America.
AI and Wearable Devices for Type 2 Diabetes
A meta-review from the University at Buffalo examines AI-enhanced wearable devices for Type 2 diabetes and prediabetes. The study finds predictive benefits and important limits, and calls for larger, more transparent studies before routine clinical use.
